Skip to main content
Top
Published in: Thrombosis Journal 1/2014

Open Access 01-12-2014 | Original clinical investigation

Enhanced pre-operative thrombolytic status is associated with the incidence of deep venous thrombosis in patients undergoing total knee arthroplasty

Authors: Yukinori Tamura, Shigeshi Mori, Shigeki Asada, Naoyuki Kawao, Shigeru Ueshima, Hiroshi Kaji, Junichiro Yamamoto, Masao Akagi, Osamu Matsuo

Published in: Thrombosis Journal | Issue 1/2014

Login to get access

Abstract

Background

Deep venous thrombosis (DVT), which is often associated with pulmonary embolism (PE), is a serious complication after total knee arthroplasty (TKA). In the present study, we examined the overall thrombotic and thrombolytic status using Global Thrombosis Test (GTT) in non-anticoagulated blood of patients undergoing TKA to develop the predictable marker for the incidence of DVT.

Methods

DVT was diagnosed using doppler ultrasonography a day after the surgery in 31 patients with osteoarthritis (n = 24), rheumatoid arthritis (n = 6) and ankylosing spondylitis (n = 1) by the well-trained operator. We measured overall thrombotic and thrombolytic status using GTT and other biomarkers, which is associated with blood coagulation and fibrinolysis, before and immediately after the surgery.

Results

Newly-generated DVT during the operation was detected in 11 of 31 patients (35.4%) 1 day after TKA. There were no differences in markers of coagulation (PT and APTT), platelet activity (platelet aggregation-induced by ADP and collagen) and fibrinolysis (FDP and D-dimer) between non-DVT and DVT group both before and after the surgery. Both Pre- and Post-operative GTT-occlusion times (OT), an index of platelet reactivity, were tended to be shorter, but not significant, in DVT group compared with non-DVT group. Pre-operative GTT-lysis time (LT), an index of thrombolytic activity, was significantly shorter in DVT group compared with non-DVT group, while there were no differences in post-operative value of this index between DVT group and non-DVT group, suggesting overall thrombolytic activity was enhanced in DVT group before surgery.

Conclusions

Our data suggest that enhancement of pre-operative thrombolytic activity assessed by GTT may be a predictable marker for the incidence of DVT after TKA.
Appendix
Available only for authorised users
Literature
2.
go back to reference Huisman MV, Klok FA: Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost 2013, 11: 412-422.CrossRefPubMed Huisman MV, Klok FA: Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost 2013, 11: 412-422.CrossRefPubMed
3.
go back to reference Carrier M, Righini M, Le Gal G: Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost 2012, 10: 1486-1490.CrossRefPubMed Carrier M, Righini M, Le Gal G: Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost 2012, 10: 1486-1490.CrossRefPubMed
5.
go back to reference Nikolaou VS, Desy NM, Bergeron SG, Antoniou J: Total knee replacement and chemical thromboprophylaxis: current evidence. Curr Vasc Pharmacol 2011, 9: 33-41.CrossRefPubMed Nikolaou VS, Desy NM, Bergeron SG, Antoniou J: Total knee replacement and chemical thromboprophylaxis: current evidence. Curr Vasc Pharmacol 2011, 9: 33-41.CrossRefPubMed
6.
go back to reference Yamaguchi T, Hasegawa M, Niimi R, Sudo A: Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty. Thromb Res 2010, 126: e323-e326.CrossRefPubMed Yamaguchi T, Hasegawa M, Niimi R, Sudo A: Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty. Thromb Res 2010, 126: e323-e326.CrossRefPubMed
7.
go back to reference Pabinger I, Ay C: Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009, 29: 332-336.CrossRefPubMed Pabinger I, Ay C: Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009, 29: 332-336.CrossRefPubMed
8.
go back to reference Hou H, Ge Z, Ying P, Dai J, Shi D, Xu Z, Chen D, Jiang Q: Biomarkers of deep venous thrombosis. J Thromb Thrombolysis 2012, 34: 335-346.CrossRefPubMed Hou H, Ge Z, Ying P, Dai J, Shi D, Xu Z, Chen D, Jiang Q: Biomarkers of deep venous thrombosis. J Thromb Thrombolysis 2012, 34: 335-346.CrossRefPubMed
9.
go back to reference Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA: Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 2010, 55: 2107-2115.CrossRefPubMed Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA: Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 2010, 55: 2107-2115.CrossRefPubMed
10.
go back to reference Gorog DA, Sweeny JM, Fuster V: Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol 2009, 6: 365-373.PubMed Gorog DA, Sweeny JM, Fuster V: Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol 2009, 6: 365-373.PubMed
11.
go back to reference Bouman HJ, Van Werkum JW, Hackeng CM, Verheugt FW, Ten Berg JM: The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008, 6: 1040-1042.CrossRefPubMed Bouman HJ, Van Werkum JW, Hackeng CM, Verheugt FW, Ten Berg JM: The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008, 6: 1040-1042.CrossRefPubMed
12.
go back to reference Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA: The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009, 20: 7-11.CrossRefPubMed Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA: The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009, 20: 7-11.CrossRefPubMed
13.
go back to reference Suehiro A, Wakabayashi I, Yamashita T, Yamamoto J: Attenuation of spontaneous thrombolytic activity measured by the global thrombosis test in male habitual smokers. J Thromb Thrombolysis 2014, 37: 414-418.CrossRefPubMed Suehiro A, Wakabayashi I, Yamashita T, Yamamoto J: Attenuation of spontaneous thrombolytic activity measured by the global thrombosis test in male habitual smokers. J Thromb Thrombolysis 2014, 37: 414-418.CrossRefPubMed
14.
go back to reference Ijiri Y, Ikarugi H, Tamura Y, Ura M, Morishita M, Hamada A, Mori M, Mori H, Yamori Y, Ishii H, Yamamoto J: Antithrombotic effect of taurine in healthy Japanese people may be related to an increased endogenous thrombolytic activity. Thromb Res 2013, 131: 158-161.CrossRefPubMed Ijiri Y, Ikarugi H, Tamura Y, Ura M, Morishita M, Hamada A, Mori M, Mori H, Yamori Y, Ishii H, Yamamoto J: Antithrombotic effect of taurine in healthy Japanese people may be related to an increased endogenous thrombolytic activity. Thromb Res 2013, 131: 158-161.CrossRefPubMed
15.
go back to reference Yamamoto J, Yamashita T, Ikarugi H, Taka T, Hashimoto M, Ishii H, Watanabe S, Kovacs IB: Gorog Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis 2003, 14: 31-39.CrossRefPubMed Yamamoto J, Yamashita T, Ikarugi H, Taka T, Hashimoto M, Ishii H, Watanabe S, Kovacs IB: Gorog Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis 2003, 14: 31-39.CrossRefPubMed
17.
go back to reference Reitsma PH, Versteeg HH, Middeldorp S: Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012, 32: 563-568.CrossRefPubMed Reitsma PH, Versteeg HH, Middeldorp S: Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012, 32: 563-568.CrossRefPubMed
18.
19.
go back to reference Goodacre S, Sampson FC, Sutton AJ, Mason S, Morris F: Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. QJM 2005, 98: 513-527.CrossRefPubMed Goodacre S, Sampson FC, Sutton AJ, Mason S, Morris F: Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. QJM 2005, 98: 513-527.CrossRefPubMed
20.
go back to reference Luxembourg B, Schwonberg J, Hecking C, Schindewolf M, Zgouras D, Lehmeyer S, Lindhoff-Last E: Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis. Thromb Haemost 2012, 107: 369-378.CrossRefPubMed Luxembourg B, Schwonberg J, Hecking C, Schindewolf M, Zgouras D, Lehmeyer S, Lindhoff-Last E: Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis. Thromb Haemost 2012, 107: 369-378.CrossRefPubMed
21.
go back to reference Fancher TL, White RH, Kravitz RL: Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ 2004, 329: 821.PubMedCentralCrossRefPubMed Fancher TL, White RH, Kravitz RL: Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ 2004, 329: 821.PubMedCentralCrossRefPubMed
22.
go back to reference Shiota N, Sato T, Nishida K, Matsuo M, Takahara Y, Mitani S, Murakami T, Inoue H: Changes in LPIA D-dimer levels after total hip or knee arthroplasty relevant to deep-vein thrombosis diagnosed by bilateral ascending venography. J Orthop Sci 2002, 7: 444-450.CrossRefPubMed Shiota N, Sato T, Nishida K, Matsuo M, Takahara Y, Mitani S, Murakami T, Inoue H: Changes in LPIA D-dimer levels after total hip or knee arthroplasty relevant to deep-vein thrombosis diagnosed by bilateral ascending venography. J Orthop Sci 2002, 7: 444-450.CrossRefPubMed
23.
go back to reference Bounameaux H, Miron MJ, Blanchard J, De Moerloose P, Hoffmeyer P, Leyvraz PF: Measurement of plasma D-dimer is not useful in the prediction or diagnosis of postoperative deep vein thrombosis in patients undergoing total knee arthroplasty. Blood Coagul Fibrinolysis 1998, 9: 749-752.CrossRefPubMed Bounameaux H, Miron MJ, Blanchard J, De Moerloose P, Hoffmeyer P, Leyvraz PF: Measurement of plasma D-dimer is not useful in the prediction or diagnosis of postoperative deep vein thrombosis in patients undergoing total knee arthroplasty. Blood Coagul Fibrinolysis 1998, 9: 749-752.CrossRefPubMed
24.
go back to reference Harper P, Marson C, Grimmer A, Monahan K, Humm G, Baker B: The rapid whole blood agglutination d-dimer assay has poor sensitivity for use as an exclusion test in suspected deep vein thrombosis. N Z Med J 2001, 114: 61-64.PubMed Harper P, Marson C, Grimmer A, Monahan K, Humm G, Baker B: The rapid whole blood agglutination d-dimer assay has poor sensitivity for use as an exclusion test in suspected deep vein thrombosis. N Z Med J 2001, 114: 61-64.PubMed
25.
go back to reference Becattini C, Lignani A, Masotti L, Forte MB, Agnelli G: D-dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thrombolysis 2012, 33: 48-57.CrossRefPubMed Becattini C, Lignani A, Masotti L, Forte MB, Agnelli G: D-dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thrombolysis 2012, 33: 48-57.CrossRefPubMed
26.
go back to reference Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L: Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994, 24: 1091-1097.CrossRefPubMed Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L: Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994, 24: 1091-1097.CrossRefPubMed
27.
go back to reference Saraf S, Wellsted D, Sharma S, Gorog DA: Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. Thromb Res 2009, 124: 447-451.CrossRefPubMed Saraf S, Wellsted D, Sharma S, Gorog DA: Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. Thromb Res 2009, 124: 447-451.CrossRefPubMed
28.
go back to reference Kovacs IB, Gorog DA, Yamamoto J: Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis 2006, 21: 221-227.CrossRefPubMed Kovacs IB, Gorog DA, Yamamoto J: Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis 2006, 21: 221-227.CrossRefPubMed
29.
go back to reference Gorog DA: Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 2010, 55: 2701-2709.CrossRefPubMed Gorog DA: Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 2010, 55: 2701-2709.CrossRefPubMed
30.
go back to reference Dahl OE, Pedersen T, Kierulf P, Westvik AB, Lund P, Arnesen H, Seljeflot I, Abdelnoor M, Lyberg T: Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993, 70: 451-458.CrossRefPubMed Dahl OE, Pedersen T, Kierulf P, Westvik AB, Lund P, Arnesen H, Seljeflot I, Abdelnoor M, Lyberg T: Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993, 70: 451-458.CrossRefPubMed
Metadata
Title
Enhanced pre-operative thrombolytic status is associated with the incidence of deep venous thrombosis in patients undergoing total knee arthroplasty
Authors
Yukinori Tamura
Shigeshi Mori
Shigeki Asada
Naoyuki Kawao
Shigeru Ueshima
Hiroshi Kaji
Junichiro Yamamoto
Masao Akagi
Osamu Matsuo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2014
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-12-11

Other articles of this Issue 1/2014

Thrombosis Journal 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.